- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04119232
Randomized Clinical Trial to Increase Physical Activity After a a Hypertensive Pregnancy (STEPUP)
December 11, 2020 updated by: University of Pennsylvania
A Randomized, Clinical Trial Evaluating Methods to Increase Physical Activity After a Pregnancy Complicated by a Hypertensive Disorder
STEPUP is a 12-week randomized clinical trial among 126 postpartum women with pregnancies complicated by hypertensive disorders.
Participants will be randomized to a control arm and receive a Fitbit or an intervention arm.
The intervention arm will receive a Fitbit and set a step count goal, receive daily feedback via text about whether they reached their goal, and will be placed in virtual teams with other participants where they can win points for their team if they meet their daily goals.
The main study outcomes will be increase in mean step count and change in psychosocial survey measures.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Women with hypertensive disorders of pregnancy, such as preeclampsia and gestational hypertension, are at elevated risk of developing hypertension, diabetes, heart failure, and premature atherosclerotic cardiovascular disease.
Current guidelines recommend intensive lifestyle modification for women with a history of hypertensive disorders in pregnancy in order to reduce the risk of developing cardiometabolic risk factors or overt CV disease.
However, limited research exists to guide how to implement lifestyle modification for this population.
The postpartum period poses unique challenges to adopting a healthy lifestyle.
Remote interventions using mobile technology may be particularly effective.
Social incentives designed using insights from behavioral economics have been demonstrated to motivate health behavior change, such as increasing physical activity.
The objective of this study is to use a randomized clinical trial to test the effectiveness of a 12-week team-based, mobile health interventions using wearable devices and social incentives to increase physical activity in the postpartum period.
Study Type
Interventional
Enrollment (Actual)
128
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Delivered a live baby at HUP or PAH within 4.0-12.6 weeks prior to study enrollment;
- Diagnosis of chronic hypertension, gestational hypertension, or preeclampsia during most recent pregnancy;
- Participating in Heart Safe Motherhood (HSM) program;
- Ability to read and provide informed consent to participate in the study;
- Has smartphone and email address
Exclusion Criteria:
- Does not speak English
- Answers yes to any of the following questions:
- Are you currently participating in any other physical activity studies?
- Do you have any medical conditions or other reasons why you could not participate in a 12-week physical activity program?
- Participants will be excluded after completing the baseline period if their baseline step count is too high (greater than or equal to 10,000 steps per day).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment.
|
|
Experimental: Social incentives-based program
Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment.
Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
|
Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment.
Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mean daily steps
Time Frame: weeks 3 to 14 of the intervention
|
Change in mean daily step count from the baseline period (weeks 1-2) to the intervention period (weeks 3-14)
|
weeks 3 to 14 of the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participant-days that step goals are achieved
Time Frame: weeks 3 to 14 of the intervention
|
proportion of days participants meet their step goal
|
weeks 3 to 14 of the intervention
|
Mean daily steps during the 12-week intervention period adjusted for baseline step count
Time Frame: 12-week intervention period
|
Mean daily steps during the 12-week intervention period adjusted for baseline step count
|
12-week intervention period
|
Change in perceived social support scale
Time Frame: weeks 3 to 14 of the intervention
|
As measured by the "multidimensional scale of perceived social support", MS-PSS -- a 12-item scale designed to measure perceived social support from three sources: Family, Friends, and a Significant Other.
Scored 1-12, with 1 having the lowest support and 12 having high support.
|
weeks 3 to 14 of the intervention
|
Change in Edinburgh postnatal depression scale (EPDS)
Time Frame: weeks 3 to 14 of the intervention
|
Change in Edinburgh postnatal depression scale (EPDS): scored 0-30 with a score of 10 or greater indicating depressive symptoms
|
weeks 3 to 14 of the intervention
|
Change in Systolic blood pressure
Time Frame: weeks 3 to 14 of the intervention
|
weeks 3 to 14 of the intervention
|
|
Change in Diastolic blood pressure
Time Frame: weeks 3 to 14 of the intervention
|
weeks 3 to 14 of the intervention
|
|
Change in weight
Time Frame: weeks 3 to 14 of the intervention
|
weeks 3 to 14 of the intervention
|
|
Change in hypertension diagnosis
Time Frame: weeks 3 to 14 of the intervention
|
weeks 3 to 14 of the intervention
|
|
Health care utilization (attended postpartum OB visit or postpartum visit with primary care or cardiology)
Time Frame: weeks 3 to 14 of the intervention
|
weeks 3 to 14 of the intervention
|
|
Change in breastfeeding rates
Time Frame: weeks 3 to 14 of the intervention
|
weeks 3 to 14 of the intervention
|
|
Change in sleep duration as measured by Fitbit
Time Frame: weeks 3 to 14 of the intervention
|
weeks 3 to 14 of the intervention
|
|
Moderate or vigorous activity, as measured by Fitbit
Time Frame: weeks 3 to 14 of the intervention
|
weeks 3 to 14 of the intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 10, 2019
Primary Completion (Actual)
June 18, 2020
Study Completion (Actual)
October 5, 2020
Study Registration Dates
First Submitted
October 7, 2019
First Submitted That Met QC Criteria
October 7, 2019
First Posted (Actual)
October 8, 2019
Study Record Updates
Last Update Posted (Actual)
December 14, 2020
Last Update Submitted That Met QC Criteria
December 11, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 833609
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preeclampsia
-
MemorialCare Health SystemNot yet recruitingPreeclampsia | Preeclampsia Postpartum | Preeclampsia Severe | Preeclampsia Mild
-
Christiana Care Health ServicesActive, not recruitingPre-Eclampsia | Preeclampsia | Preterm | Preeclampsia Severe | Preeclampsia Second Trimester | Preeclampsia Complicating Childbirth | Preeclampsia PuerperiumUnited States
-
University Medical Centre LjubljanaCompletedPreeclampsia Postpartum | Preeclampsia SevereSlovenia
-
Cedars-Sinai Medical CenterThermoFisher Scientific Brahms Biomarkers FranceCompletedGestational Hypertension | Preeclampsia Severe | Preeclampsia and Eclampsia | Chronic Hypertension in Obstetric Context | Superimposed Pre-Eclampsia | Preeclampsia MildUnited States
-
Washington University School of MedicineRecruitingPreeclampsia Postpartum | Preeclampsia SevereUnited States
-
Brigham and Women's HospitalCompletedHypertension in Pregnancy | Postpartum | Postpartum Preeclampsia | Gestational Hypertension | Preeclampsia SevereUnited States
-
Christiana Care Health ServicesNot yet recruitingPreterm Birth Complication | Preeclampsia Severe | Preeclampsia Second TrimesterUnited States
-
AMAG Pharmaceuticals, Inc.TerminatedSevere PreeclampsiaUnited States, Poland, South Africa
-
Mpilo Central HospitalCompletedSevere PreeclampsiaZimbabwe
Clinical Trials on Social incentives-based program
-
The University of Hong KongUniversity Grants Committee, Hong KongRecruitingDiabetes Mellitus, Type 2Hong Kong
-
The University of Hong KongUniversity Grants Committee, Hong KongCompletedDiabetes Mellitus, Type 2Hong Kong
-
University of PennsylvaniaCompleted
-
University of Illinois at ChicagoNot yet recruitingBurnout, Professional | Stress, Psychological | Anxiety | Prosocial Behavior | Efficacy, Self | Self-Compassion | Optimism | Social Competence | Self Awareness | Community SenseUnited States
-
Kathmandu University School of Medical SciencesCompleted
-
University of PennsylvaniaCompletedPatients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)United States
-
Western University, CanadaPublic Health Agency of Canada (PHAC)Terminated
-
Abramson Cancer Center at Penn MedicineNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingPhysical ActivityUnited States
-
The Miriam HospitalUnknown
-
University of PennsylvaniaCompleted